Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV000693205 | SCV000821065 | uncertain significance | Myofibrillar myopathy 5; Distal myopathy with posterior leg and anterior hand involvement; Hypertrophic cardiomyopathy 26; Dilated Cardiomyopathy, Dominant | 2020-05-11 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals with FLNC-related disease. This variant is present in population databases (rs766513255, ExAC 0.002%). This sequence change replaces glycine with arginine at codon 1381 of the FLNC protein (p.Gly1381Arg). The glycine residue is highly conserved and there is a moderate physicochemical difference between glycine and arginine. |
| Ambry Genetics | RCV002332439 | SCV002627227 | uncertain significance | Cardiovascular phenotype | 2021-07-12 | criteria provided, single submitter | clinical testing | The p.G1381R variant (also known as c.4141G>A), located in coding exon 24 of the FLNC gene, results from a G to A substitution at nucleotide position 4141. The glycine at codon 1381 is replaced by arginine, an amino acid with dissimilar properties. This amino acid position is conserved. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |